AIDS and Behavior

, Volume 22, Issue 4, pp 1323–1328 | Cite as

Prescription Opioid Use is Associated with Virologic Failure in People Living with HIV

  • John Flores
  • Yuanyuan Liang
  • Norma S. Ketchum
  • Barbara J. Turner
  • Delia Bullock
  • Roberto Villarreal
  • Jennifer S. Potter
  • Barbara S. Taylor
Brief Report


Prescription opioid misuse is a rising epidemic in the U.S., and people living with HIV are at increased risk. We assessed the association between prescription opioid use and virologic failure in HIV+ patients in the South Texas HIV Cohort. We found prescription opioid use was significantly associated with virologic failure, after adjustment for age, race, gender, insurance status, years living with HIV, reported HIV risk factor, chronic hepatitis C virus infection, current substance abuse, and care engagement. These findings suggest that opioid analgesic use may have negative consequences beyond misuse in people living with HIV.


Prescription opioid HIV Virologic outcome Narcotic 



We gratefully acknowledge the faculty and staff at the FFACTS HIV outpatient clinic of University Health System. We also gratefully acknowledge the faculty and staff at the University of Texas Health Science Center at San Antonio. We would like to thank the Clinical and Translational Science Award program for their Pilot Funding Award CTSA 1 UL1 RR025767, and the National Institutes of Health K23 Career Development Award 7K23AI081538.


The study was funded by the CTSA Pilot funding award CTSA1 UL1 RR025767 and NIH K23 Career Development Award 7K23AI081538.

Compliance with Ethical Standards

Conflict of interest

The authors of this manuscript declare no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

The University of Texas Health Science Center San Antonio Institutional Review Board determined that individual patient consent could be waived for this study, as this is a retrospective analysis of existing electronic medical records data.”

Research Involving Human Participants and/or Animals

Human subjects activities under this study was approved by the University of Texas Health Science Center San Antonio Institutional Review Board.


  1. 1.
    Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in san francisco. AIDS Behav. 2014;18(7):1352–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Turner AN, Maierhofer C, Funderburg NT, Sydney B, et al. High levels of self-reported prescription opioid use by HIV-positive individuals. AIDS care. 2016;28(12):1559–65.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Silverberg MJ, Ray GT, Saunders K, et al. Prescription long-term opioid use in HIV-infected patients. Clin J Pain. 2012;28(1):39–46.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Edelman EJ, Gordon K, Becker WC, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28(1):82–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Masur H, Brooks JT, Benson CA, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the centers for disease control and prevention, national institutes of health, and HIV medicine association of the infectious diseases society of america. Clin Infect Dis. 2014;58(9):1308–11.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: role for both daily and total opioid dose? J Pain. 2015;16(4):318–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Robinson-Papp J, Elliot K, Simpson D, Morgello S. Problematic prescription opioid use in an HIV-infected cohort: the importance of universal toxicology testing. J Acquir Immune Defic Syndr. 2012;61(2):187–93.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vijayaraghavan M, Penko J, Guzman D, Miaskowski C, Kushel M. Primary care providers’ judgments of opioid analgesic misuse in a community-based cohort of HIV-infected indigent adults. J Gen Intern Med. 2011;26(4):412–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Tsao JC, Stein JA, Dobalian A. Pain, problem drug use history, and aberrant analgesic use behaviors in persons living with HIV. Pain. 2007;133(1–3):128–37.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lum P, Little S, Botski M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011;56(1):91–7.CrossRefGoogle Scholar
  11. 11.
    Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed 08 Nov 2016, p. H-2, “Virologic Suppression”.
  12. 12.
    Meng J, Sindberg GM, Roy S. Disruption of gut homeostasis by opioids accelerates HIV disease progression. Front Microbiol. 2015;6(643):1–11.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.University of Illinois Hospital and Health Sciences SystemChicagoUSA
  2. 2.Department of Infectious DiseaseUniversity of Texas Health Science Center San AntonioSan AntonioUSA
  3. 3.University Health SystemSan AntonioUSA
  4. 4.Research to Advance Community Health (ReACH) CenterUniversity of Texas Health Science Center San AntonioSan AntonioUSA
  5. 5.Department of Epidemiology and Public Health, School of MedicineUniversity of MarylandBaltimoreUSA

Personalised recommendations